Skip to main navigation Skip to search Skip to main content

Assessment of GFR in Patients with Cancer Part 2: Anticancer Therapies - Perspectives from the American Society of Onco-Nephrology (ASON)

  • Abhijat Kitchlu
  • , Verônica T.Costa E. Silva
  • , Shuchi Anand
  • , Jaya Kala
  • , Ala Abudayyeh
  • , Lesley A. Inker
  • , Mitchell H. Rosner
  • , Sabine Karam
  • , Prakash Gudsoorkar
  • , Shruti Gupta
  • , Sheldon Chen
  • , Nattawat Klomjit
  • , Nelson Leung
  • , Tomaz Milanez
  • , Shveta S. Motwani
  • , Sheikh B. Khalid
  • , Vinay Srinivasan
  • , Rimda Wanchoo
  • , Jan H. Beumer
  • , Geoffrey Liu
  • Nizar M. Tannir, Ani Orchanian-Cheff, Yimin Geng, Sandra M. Herrmann

Research output: Contribution to journal › Article › peer-review

Original languageEnglish (US)
Pages (from-to)1073-1077
Number of pages5
JournalClinical Journal of the American Society of Nephrology
Volume19
Issue number8
DOIs
StatePublished - Aug 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CKD
  • cancer
  • chemotherapy
  • clinical trial
  • cockcroft-gault
  • creatinine
  • drug metabolism
  • drug nephrotoxicity
  • kidney cancer
  • onconephrology

Cite this